Published in Ann Oncol on February 22, 2012
Association between bone scan index and activities of daily living in patients with advanced non-small cell lung cancer. Support Care Cancer (2017) 1.08
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci (2014) 0.83
In vivo selection for spine-derived highly metastatic lung cancer cells is associated with increased migration, inflammation and decreased adhesion. Oncotarget (2015) 0.81
Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol (2014) 0.78
Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study. Mol Clin Oncol (2014) 0.78
Hospital use among patients with lung cancer complicated by bone metastases and skeletal- related events: a population-based cohort study in Denmark. Clin Epidemiol (2015) 0.77
Factors Associated with Life Expectancy in Patients with Metastatic Spine Disease from Adenocarcinoma of the Lung. Global Spine J (2015) 0.75
Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report. Asia Ocean J Nucl Med Biol (2014) 0.75
Thoracic Temporal Subtraction Three Dimensional Computed Tomography (3D-CT): Screening for Vertebral Metastases of Primary Lung Cancers. PLoS One (2017) 0.75
Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open (2017) 0.75
Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors. Int J Clin Oncol (2017) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med (2010) 29.06
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Skeletal complications of malignancy. Cancer (1997) 5.41
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Bisphosphonates for breast cancer. Cochrane Database Syst Rev (2005) 3.24
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer (2007) 2.88
Malignant bone pain: pathophysiology and treatment. Pain (1997) 2.75
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.49
Economic burden of metastatic bone disease in the U.S. Cancer (2007) 2.31
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Adverse effects of bisphosphonates: current issues. J Support Oncol (2008) 1.90
Renal failure with the use of zoledronic acid. N Engl J Med (2003) 1.89
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer (2008) 1.57
High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys (2001) 1.49
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology (2004) 1.47
Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer (2008) 1.35
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer (2003) 1.32
Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol (2006) 1.28
The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) (2010) 1.25
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer (2004) 1.20
Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer (2004) 1.20
Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant (1997) 1.15
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer (2004) 1.11
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer (2004) 1.10
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain (2004) 1.08
Adverse effects of bisphosphonates. Calcif Tissue Int (2010) 1.04
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res (2008) 1.01
Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage (2005) 0.95
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer (2010) 0.93
Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol (2009) 0.90
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer (2008) 0.87
Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm (2009) 0.85
Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer (2006) 0.85
Family factors influencing cancer pain management. Postgrad Med J (1991) 0.83
Palliative care. Some organisational considerations. Minerva Anestesiol (2005) 0.81
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Oncol Res (2009) 0.80
The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -. Asian Spine J (2008) 0.80
[Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis]. Clin Calcium (2008) 0.79
[The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer]. Pneumonol Alergol Pol (1998) 0.78
[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers]. Nan Fang Yi Ke Da Xue Xue Bao (2010) 0.78
Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. J BUON (2007) 0.78
Effects of cisplatin on parathyroid hormone- and human lung tumor-induced bone resorption. J Bone Miner Res (1988) 0.77
[Incidence and imaging characteristics of skeletal metastases detected by bone scintigraphy in lung cancer patients]. Vojnosanit Pregl (2006) 0.76
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer (1993) 2.08
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88
Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology (2010) 1.88
Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria. J Infect Dis (2001) 1.44
Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol (1996) 1.42
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer (2010) 1.23
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res (1998) 1.21
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res (2000) 1.19
Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol (2011) 1.18
ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol (2013) 1.17
The combined effect of smoking and coffee drinking on LDL and HDL cholesterol. Circulation (1979) 1.17
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol (2003) 1.14
Induction treatment before surgery for non-small cell lung cancer. Lung Cancer (2003) 1.12
Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res (1997) 1.12
Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res (1997) 1.11
'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol (2000) 1.08
Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol (1997) 1.05
Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol (1997) 1.00
Endoscopic papillectomy: a novel approach to difficult cannulation. Gut (1996) 0.99
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol (1999) 0.99
Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer (2011) 0.96
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer (1999) 0.95
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ (2009) 0.94
Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol (1999) 0.94
The influence of immobilization on osteocyte morphology: osteocyte differential count and electron microscopical studies. Virchows Arch A Pathol Anat Histol (1976) 0.92
Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer (2003) 0.92
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer (1994) 0.92
Endobronchial ultrasound (EBUS)--assessment of a new diagnostic tool in bronchoscopy for staging of lung cancer. Onkologie (2001) 0.91
Cardiovascular mortality in transient ischemic attacks. Stroke (1980) 0.89
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol (2009) 0.88
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death Dis (2013) 0.87
Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol (1986) 0.86
Invasive thymoma: treatment with postoperative radiation therapy. Radiology (1997) 0.86
Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer. Semin Oncol (1994) 0.86
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Invest New Drugs (1999) 0.85
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. Ann Oncol (2012) 0.85
Induction of granulocyte colony-stimulating factor by acute febrile infection but not by neutropenia in HIV-seropositive individuals. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.85
Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer (2006) 0.84
Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol (1996) 0.84
Primary mediastinal B-cell lymphoma: update of its clinicopathologic features. Leuk Lymphoma (1997) 0.83
Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer (2010) 0.83
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2007) 0.82
Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer (1993) 0.82
[Trypanosomiasis in a woman from Cameroon mimicking systemic lupus erythematosus]. Dtsch Med Wochenschr (2004) 0.82
Molecular approaches to diagnosis and management of ovarian cancer. Cancer Metastasis Rev (1997) 0.82
Combined effects of ionizing radiation and 4-hydroperoxyfosfamide in vitro. Radiother Oncol (1998) 0.81
Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemother Pharmacol (1996) 0.81
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol (2013) 0.81
A phase II study of caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother Pharmacol (2001) 0.81
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab (1999) 0.81
Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J (2005) 0.80
Topotecan--a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol (1999) 0.80
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer (1999) 0.80
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol (1996) 0.80
Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up. Eur J Cancer (1995) 0.79
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer (2004) 0.79
A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann Oncol (1998) 0.79
Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett (1996) 0.78
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol (2016) 0.78
Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer. Clin Oncol (R Coll Radiol) (2008) 0.78
Ifosfamide and docetaxel in non-small cell lung cancer. Semin Oncol (1998) 0.78
An update on European randomized studies in non-small cell lung cancer. Semin Oncol (1998) 0.77
Vascularization of malignant testicular tumors. Urology (1985) 0.77
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner (1993) 0.77
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol (2003) 0.76
Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs. Cancer Treat Rep (1984) 0.76
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Ir J Med Sci (2014) 0.76
[Sequential methotrexate and fluorouracil in metastasizing colorectal carcinomas. Results of a phase II pilot study (author's transl)]. Dtsch Med Wochenschr (1982) 0.76
Imaging of tumor viability in lung cancer: initial results using 23Na-MRI. Rofo (2012) 0.76
[Disseminated microspiridiosis (Encephalitozoon intestinalis) in a patient with HIV infection]. Dtsch Med Wochenschr (2003) 0.76
Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer. Semin Oncol (1998) 0.75
Bartter's syndrome in two generations of an Irish family. Postgrad Med J (1993) 0.75
Chemotherapy for upper gastrointestinal tumours. Postgrad Med J (2000) 0.75
Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer (2000) 0.75
Phase II trial of coumarin and cimetidine in advanced renal cell carcinoma. Ann Oncol (1990) 0.75
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer (2003) 0.75
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Br J Cancer (2000) 0.75
A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Ir J Med Sci (2011) 0.75
Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study. Ann Oncol (2001) 0.75
[Needle biopsy of the iliac crest in the diagnosis of bone and bone marrow diseases. Indication, technic and value of evidence]. Dtsch Med Wochenschr (1984) 0.75
[Reduction of hypertensive changes in the electrocardiogram during antihypertensive treatment]. MMW Munch Med Wochenschr (1979) 0.75
[Proceedings: Pathogenesis of immobilization osteoporosis (morphologic studies)]. Verh Dtsch Ges Pathol (1975) 0.75
Etoposide, adriamycin, and cisplatinum (EAP) combination chemotherapy for advanced gastric cancer. A phase II trial by the "Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)". Onkologie (1990) 0.75
Fever due to 6-mercaptopurine. Cancer Treat Rep (1982) 0.75
[Regression of left ventricular hypertophy in the ECG during antihypertensive treatment: preliminary observations (author's transl)]. Dtsch Med Wochenschr (1979) 0.75
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. Lung Cancer (2006) 0.75
[Electrocardiographic signs of hypokalemia under antihypertensive treatment (author's transl)]. Schweiz Rundsch Med Prax (1979) 0.75
Peritoneal dialysis in maple-syrup-urine disease: studies on branched-chain amino and keto acids. Eur J Pediatr (1980) 0.75
[Left axis deviation and left anterior hemiblock in patients with essential hypertension during antihypertensive treatment (author's transl)]. Herz (1980) 0.75
Skeletal homeostasis and ageing. Studies in human femora. Calcif Tissue Res (1977) 0.75
[Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)]. Klin Wochenschr (1980) 0.75
[Angina pectoris during regional chemotherapy of liver metastases]. Dtsch Med Wochenschr (1987) 0.75